Raymond Yang

1 month ago | biorxiv.org | Justin Tang |Raymond Yang

AbstractAcquired chemoresistance, often linked to metabolic adaptation, severely limits therapeutic efficacy in non-small cell lung cancer (NSCLC). Strategies targeting resistance-associated metabolic plasticity are urgently needed. Here, we investigated the combination of Metformin (mitochondrial Complex I inhibitor) and Dichloroacetate (DCA; PDK inhibitor) in chemo-sensitive human A549 NSCLC cells and an acquired Doxorubicin-resistant subline (A549-DR).

1 month ago | biorxiv.org | Justin Tang |John Miller |Raymond Yang

AbstractBackground:Immune-checkpoint blockade transformed melanoma therapy, yet the canonical B16-F10 model resists programmed cell-death-1 (PD-1) inhibition. Housing mice below thermoneutrality, specifically at 22 degrees Celsius, causes cold stress, and dosing outside the circadian immune peak dampens anti-tumour immunity. We hypothesised that eliminating both these factors would render B16-F10 curable.

2 months ago | preprints.org | Justin Tang |Raymond Yang

You are already at the latest version Background: Glioblastoma (GBM) remains a devastating brain malignancy characterized by cellular heterogeneity and therapy resistance. Cancer stem-like cells (CSCs) within GBM are implicated as drivers of tumor progression and resistance to the standard-of-care chemotherapy, temozolomide (TMZ). O⁶-methylguanine-DNA methyltransferase (MGMT) expression mediates resistance by repairing TMZ-induced DNA damage.